Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Economic Woes Hit Biotech Firms ...
by Ann M. Thayer
December 8, 2008
| A version of this story appeared in
Volume 86, Issue 49
South San Francisco-based Titan Pharmaceuticals is cutting 40% of its workforce to save cash. The remaining staff of about 25, which is likely to be further cut, will conduct minimal development efforts to keep the company's Phase III probuphine opioid addiction treatment afloat until it can partner or sell the program. Meanwhile, Enzon Pharmaceuticals, in Bridgewater, N.J., cites poor market conditions as the reason it has decided not to spin off its biotech business as a separate company.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter